Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib maintenance and long-term extension study in Crohn's disease after M14-431 or M14-433
CTR20181737Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc.. Started Mar 2019; status: active.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20181737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181737.